New diagnostic strategy aims to end diagnostic odyssey for rare diseases
NCT ID NCT03163771
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new approach to diagnose peroxisomal disorders, a group of rare genetic diseases. The strategy uses advanced metabolic and genetic tests to find the cause faster in people with suspicious symptoms or lab results. Researchers included 8 participants from four hospitals in France to see if this method could reduce the long delays often faced by these patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
8 people
The number who actually took part.
- Started
-
Dec 2018
- Finished
-
Aug 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The studied population is represented by only one group of patients checking the inclusion criteria and recruited in the 4 University Hospital centers (Amiens, Caen, Lille and Rouen). For each patient, diagnostic exploration will start in patients with the common inclusion criteria and will include the study of all biochemical parameters susceptible to be disturbed In peroxisomal pathologies (Biology component). Based on the data obtained, the inclusion of patients will lead to biological confirmation tests (Cell Exploration and Enzymology) and molecular studies (Molecular Biology).
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: I - CLINICAL/BIOLOGICAL CRITERIA For an efficient screening of the patients of the 4 contributing University Hospitals (Amiens, Caen, Lille and Rouen), various inclusion criteria were selected: In general, the inclusion criterion is the existence of a positive biology or in turn the persistence of a clinical suspicion in spite of a negative biology. I A - Children from 0 to 17 years: The clinical inclusion criterion is a positive biology or the persistence of a clinical suspicion in spite of a negative biology. This persistent clinical suspicion is left to the discretion of the clinician. It is essentially based on the existence of a family history of peroxisomal (or suspected) pathology and / or the combination of several clinical signs of craniofacial dysmorphism, skeletal abnormalities, encephalopathy (seizures, ataxia, Hypotonia), demyelinating peripheral neuropathy, ophthalmopathy (retinopathy, cataract), hepatic impairment (hyperbilirubinemia, hepatomegaly, cholestasis) and growth retardation OR I B - Adults from 18 years The neurological symptoms of peroxisomal diseases in adulthood are numerous and non-specific. The three inclusion criteria selected for patient selection are as follows: * Cognitive impairment (delayed acquisition or regression) and / or leukodystrophy AND At least one of the following signs: Cerebellar ataxia, Spastic paraparesis, Peripheral neuropathy, Neurosensory deafness, Retinitis pigmentosa, Epilepsy, Unexplained unexplained vigilance, Peripheral corticotropic insufficiency +/- gonadotropic AND * no evidence for an extraperoxisomal origin of the patient disease stated after the usual paraclinic explorations II - NON CLINICAL CRITERIA * Social insurances * Having understood the information note and having signed the informed consent form. * Patients under guardianship or curatorship may be included, since peroxisomal diseases as a cause of neurological impairment may potentially lead to guardianship. Exclusion Criteria: * Pregnant or nursing women * Person deprived of liberty or in emergency situations
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diagnoses disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Département de Pédiatrie, Unité de Génétique Clinique, CHU d'Amiens
Amiens, 80054, France
-
Hôpital Jeanne de Flandres, CHRU
Lille, France
-
Pédiatrie, CHU Clémenceau de Caen
Caen, 40433, France
-
Pédiatrie, Pavillon Mère et Enfant, CHU Ch. Nicolle de Rouen
Rouen, 76031, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New malaria test aims to catch hidden infections in pregnant women
- Marathon runners and heart patients put a new troponin test to the ultimate challenge
- New study aims to catch lung cancer early in french smokers
- AI boosts cataract surgery precision for severely nearsighted patients
- Does your income affect your cancer care? new study investigates
- Could a simple stool test revolutionize TB diagnosis for kids and HIV patients?